Ridazolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2R4QO1868Y. European Medicines Agency schedules Ridazolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10302MIG. Ridazolol generally arises in the molecular formula C15H18CL2N4O3. The term RIDAZOLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, no. 6, 1984, list 24.) RIDAZOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ridazolol under HS 29339990 and SITC 51577. As of Q4 2014, RIDAZOLOL remains the US FDA Preferred Term for this commodity. Ridazolol bears US NLM identifiers UMLS ID C0073362 and NCI Concept Code C76559. SMILES: CLC1C(NCCNCC(O)COC2C(CL)CCCC2)CN[NH]C1=O.